fda compounding semaglutide enforcement november 2025 news is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger to protect patients from unverified FDA to Restrict Ingredients Used
Description
The positive reviews cluster around a few themes

With semaglutide, its about 16%

How MDWatch helps seniors If you qualify for the new Medicare GLP-1 Bridge, brand-name GLP-1s can be covered for about $50/month

In most cases, the effects as gastrointestinal and you may experience: Nausea Vomiting Diarrhea Abdominal pain In addition to gastrointestinal issues, you may also experience dizziness, weakness, and confusion

You should not take Zepbound if you have a known hypersensitivity to tirzepatide or if you or a family member has been diagnosed with Multiple Endocrine Neoplasia Type 2 or Medullary Thyroid Cancer

The positive reviews that do exist praise delivery speed and medication effectiveness, but they are outweighed by the critical feedback
